CIR1

Across TCGA pan-cancer cohorts, CIR1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CIR1 data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CIR1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CIR1 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

PDAC, HNSC, and CCRCC are the cancer types where CIR1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	II,III,IV	0.288	0.560	.015	17	view →
HNSC	DFS	Median	All	0.685	0.847	.003	14	view →
CCRCC	OS	Tertile	All	0.596	1.000	.016	4	view →
LSCC	DFS	Tertile	All	0.987	0.889	.027	3	view →
LUAD	DFS	Median	II,III,IV	1.000	0.819	.034	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CIR1–PDAC (DFS)

Open the PDAC breakdown →